Critically Ill Clinical Trial
Official title:
Pharmacokinetic/Pharmacodynamic Aspects of Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs and Receiving Continuous Renal Replacement Therapy.
Verified date | August 2021 |
Source | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Colistin is an antibiotic active against several classes of multi-resistant gram-negative bacteria; the drug should be used in high doses in patients on continuous renal replacement therapy, since the drug is eliminated through the dialysis filter. This is an Open-label, Phase 4, interventional, prospective, single-center pilot study aimed to analyze the concentrations of colistin in plasma and ultrafiltrate by liquid chromatography/mass spectrometry, in 20 critically ill patients admitted to intensive care and suffering from severe infections by multi-resistant bacteria, who receive continuous renal replacement therapy.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | January 30, 2022 |
Est. primary completion date | January 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Infection where the involvement of MDR germs is documented or highly probable - Continuous renal replacement therapy - Acute renal failure, stage III of the 2012 KDIGO classification - Half-life of the continuous renal replacement therapy filter less than 48 hours. Exclusion Criteria: - State of pregnancy or breastfeeding, or patients expecting to conceive children within the projected duration of the study, starting with the screening through 30 days after the last dose of IMP treatment - Patients with a positive urine pregnancy test within 72 hours prior to study drug treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. In the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication - Women of childbearing potential - Refusal of informed consent - Known hypersensitivity to polymyxins and to excipients - Clinical condition with high probability of death, according to Symplified Acute Physiology Score (SAPS II) - Partial maintenance of renal function, defined by stages I and II of the 2012 KDIGO classification. - Renal replacement therapy filter other than AN69 ST 150 - Prior systemic treatments with any investigational agents within 4 weeks prior to the inclusion in the trial - Any other clinical condition that, in the opinion of the investigator, makes the patient unfit for the trial |
Country | Name | City | State |
---|---|---|---|
Italy | Fondazione Policlinico A.Gemelli IRCSS | Roma | Italia |
Lead Sponsor | Collaborator |
---|---|
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area under the plasma concentration versus time curve (AUC) | Colistin A and B misuration in the plasma and in the pre-post filter. | 0-12 hours | |
Primary | Peak plasma concentration | Colistin A and B misuration in the plasma | 0-12 hours | |
Primary | Half-life | Colistin A and B misuration in the plasma | 0-12 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05539521 -
Efficacy and Safety of Remimazolam Besylate Versus Propofol for Sedation in Critically Ill Patients With Deep Sedation
|
Phase 2 | |
Recruiting |
NCT04776486 -
Iohexol Clearance in Critically Ill Patients With Augmented Renal Creatinine Clearance
|
N/A | |
Completed |
NCT05766319 -
The ICU-recover Box, Using Smart Technology for Monitoring Health Status After ICU Admission
|
N/A | |
Recruiting |
NCT03231540 -
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)
|
N/A | |
Completed |
NCT02286869 -
Cardioventilatory Coupling in Critically Ill Patients
|
N/A | |
Completed |
NCT01434823 -
24 Hour Intensivist Coverage in the Medical Intensive Care Unit
|
N/A | |
Active, not recruiting |
NCT01142570 -
Effect of Enteral Nutrition Enriched in Protein and Based on Indirect Calorimetry Measurement in Chronically Critically Ill Patients
|
N/A | |
Completed |
NCT01167595 -
Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients
|
N/A | |
Not yet recruiting |
NCT00916591 -
Prokinetic Drugs and Enteral Nutrition
|
N/A | |
Completed |
NCT01293708 -
Realities, Expectations and Attitudes to Life Support Technologies in Intensive Care for Octogenarians:
|
||
Recruiting |
NCT00654797 -
Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2
|
Phase 2 | |
Withdrawn |
NCT00178321 -
Improving Sleep in the Pediatric Intensive Care Unit
|
N/A | |
Completed |
NCT01168128 -
PERFormance Enhancement of the Canadian Nutrition Guidelines by a Tailored Implementation Strategy: The PERFECTIS Study
|
N/A | |
Completed |
NCT02447692 -
Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study
|
N/A | |
Recruiting |
NCT04582760 -
Early Mobilization in Ventilated sEpsis & Acute Respiratory Failure Study
|
N/A | |
Not yet recruiting |
NCT05961631 -
Bio-electrical Impedance Analysis Derived Parameters for Evaluating Fluid Accumulation
|
||
Completed |
NCT03276650 -
Admission of Adult-onset Still Disease Patients in the ICU
|
||
Completed |
NCT03922113 -
Muscle Function After Intensive Care
|
||
Recruiting |
NCT05055830 -
Opportunistic PK/PD Trial in Critically Ill Children (OPTIC)
|
||
Recruiting |
NCT06027008 -
Mechanical Insufflation-Exsufflation (Cough Assist) in Critically Ill Adults
|
N/A |